[14C]-2-Deoxyglucose Autoradiographic Studies of Dopaminergic Drugs in an Animal Model of Parkinson’s Disease

  • Joel M. Trugman
  • G. Frederick Wooten
Part of the Advances in Behavioral Biology book series (ABBI, volume 39)


Parkinson’s disease is unique among neurological disorders in that all of its cardinal signs and symptoms can be attributed to brain dopamine deficiency and corrected by dopamine replacement. Although great progress has been made, drug treatment of patients with advanced Parkinson’s disease is severely limited by declining efficacy of dopaminergic drugs, the emergence of drug-induced dyskinesias, and the occurrence of complex clinical fluctuations. Two important questions remain regarding dopaminergic therapy: 1) Which dopamine receptors (i.e. anatomic location, receptor subtype) need to be stimulated to achieve an antiparkinson effect? 2) Subsequent to dopamine receptor stimulation, which neural circuits are activated to mediate these effects? Substantive answers to these questions may suggest new treatment strategies for Parkinson’s disease, or alternatively, more rational use of currently available drugs.


Dopamine Agonist Superior Colliculus Dopaminergic Drug Midbrain Reticular Formation Dopamine Receptor Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barone, P., Tucci, I., Parashos S.A. and Chase, T.N.: D-1 dopamine receptor changes after striatal quinolinic acid lesion. Eur. J. Pharmacol. 138: 141–145, 1987.PubMedCrossRefGoogle Scholar
  2. Goldstein, M., Lieberman, A., Lew, J.Y., Asano, T., Rosenfeld, M.R. and Makman, M.H.: Interaction of pergolide with central dopaminergic receptors. Proc. Natl. Acad. Sci. 77: 3725–3728, 1980.PubMedCrossRefGoogle Scholar
  3. Harrison, M.B., Wiley, R.G. and Wooten, G.F.: Selective localization of D1 receptors to striatonigral neurons in the rat. Soc. Neuroscí. Abs. 15: 585, 1989.Google Scholar
  4. Kadekaro, M., Crane, A.M. and Sokoloff, L.: Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc. Natl. Acad. Sci. U.S.A. 82: 6010–6013, 1985.PubMedCrossRefGoogle Scholar
  5. Mata, M., Fink, D.J., Gainer, H., Smith, C.B., Davidsen, L., Savaki, H., Schwartz, W.J. and Sokoloff, L.: Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J. Neurochem. 34 (1): 213–215, 1980.PubMedCrossRefGoogle Scholar
  6. Sokoloff, L., Reivich, M., Kennedy, C., Des Rosiers, M.H., Patlak, C.S., Pettigrew, K.D., Sakurada, 0. and Shinohara, M.: The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28: 897–916, 1977.PubMedCrossRefGoogle Scholar
  7. Trugman, J.M. and Wooten, G.F.: The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra. Brain Res. 379: 264–274, 1986.PubMedCrossRefGoogle Scholar
  8. Trugman, J.M. and Wooten, G.F.: Selective D1 and D2 dopamine agonísts differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantía nigra lesions. J. Neurosci. 7 (9): 2927–2935, 1987.PubMedGoogle Scholar
  9. Trugman, J.M., Arnold, W.S., Touchet, N. and Wooten, G.F.: Dl dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography. J. Pharmacol. Exp. Ther. 250: 1156–1160, 1989.PubMedGoogle Scholar
  10. Ungerstedt, U., Averno, A., Averno, E., Ljungberg, T. and Ranje, C.: Animal models of parkinsonísm. Adv. Neurol. 3: 257–271, 1973.Google Scholar
  11. Weick, B.G. and Walters, J.R.: Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars retículata neurons in 6-hydroxydopamine lesioned rats: Dl/D2 coactivation induces potentiated responses. Brain Res. 405: 234–246, 1987.PubMedCrossRefGoogle Scholar
  12. Wooten, G.F. and Collins, R.C.: Metabolic effects of unilateral lesion of the substantia nigra. J. Neurosci. 1: 285–291, 1981.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Joel M. Trugman
    • 1
  • G. Frederick Wooten
    • 1
  1. 1.Department of NeurologyUniversity of Virginia Health Sciences CenterCharlottesvilleUSA

Personalised recommendations